Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Elon Musk's brain-computer interface startup Neuralink secured $650 million in series E funding to expand patient access to ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase (WRN) ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Protein degradation company Plexium has laid off staff as part of a realignment to support the company’s pipeline, which is ...

Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss ...

The FDA may be facing a 4% cut to its overall budget courtesy of the Trump administration, but that hasn’t stopped the agency ...

Major medtech companies are preparing for significant financial headwinds as tariffs threaten to disrupt the $200 billion | ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in ...